RT for Breast Cancer Patients Is 'Less Scary' Than Anticipated

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video examines patient fears and misconceptions regarding radiation therapy for the treatment of breast cancer.

In this video, Narek Shaverdian, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses results of a study that surveyed patients to examine fears and misconceptions regarding radiation therapy for the treatment of breast cancer.

Shaverdian presented the results of the study (abstract 85) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held last month in San Diego.

Recent Videos
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Related Content
Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.

Complete Consolidative Radiotherapy May Have Survival Benefits in ES-SCLC

Russ Conroy
October 19th 2024
Article

Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.

Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

Durvalumab Shows Manageable Safety Profile in LS-SCLC

Roman Fabbricatore
October 10th 2024
Article

Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

Russ Conroy
October 4th 2024
Article

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

Ariana Pelosci
October 3rd 2024
Article

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC

Russ Conroy
October 3rd 2024
Article

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

177Lu-Dotatate Improves PFS in Recurrent Meningioma

Ariana Pelosci
October 1st 2024
Article

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.